Collaboration for rare disease drug discovery research
- PMID: 25685324
- PMCID: PMC4314660
- DOI: 10.12688/f1000research.5564.1
Collaboration for rare disease drug discovery research
Abstract
Rare disease research has reached a tipping point, with the confluence of scientific and technologic developments that if appropriately harnessed, could lead to key breakthroughs and treatments for this set of devastating disorders. Industry-wide trends have revealed that the traditional drug discovery research and development (R&D) model is no longer viable, and drug companies are evolving their approach. Rather than only pursue blockbuster therapeutics for heterogeneous, common diseases, drug companies have increasingly begun to shift their focus to rare diseases. In academia, advances in genetics analyses and disease mechanisms have allowed scientific understanding to mature, but the lack of funding and translational capability severely limits the rare disease research that leads to clinical trials. Simultaneously, there is a movement towards increased research collaboration, more data sharing, and heightened engagement and active involvement by patients, advocates, and foundations. The growth in networks and social networking tools presents an opportunity to help reach other patients but also find researchers and build collaborations. The growth of collaborative software that can enable researchers to share their data could also enable rare disease patients and foundations to manage their portfolio of funded projects for developing new therapeutics and suggest drug repurposing opportunities. Still there are many thousands of diseases without treatments and with only fragmented research efforts. We will describe some recent progress in several rare diseases used as examples and propose how collaborations could be facilitated. We propose that the development of a center of excellence that integrates and shares informatics resources for rare diseases sponsored by all of the stakeholders would help foster these initiatives.
Keywords: Twitter; drug discovery; patient advocacy; rare disease.
Conflict of interest statement
Figures
Similar articles
-
From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research.Orphanet J Rare Dis. 2018 Nov 6;13(1):196. doi: 10.1186/s13023-018-0936-x. Orphanet J Rare Dis. 2018. PMID: 30400963 Free PMC article. Review.
-
The project data sphere initiative: accelerating cancer research by sharing data.Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15. Oncologist. 2015. PMID: 25876994 Free PMC article.
-
Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium.Ther Adv Rare Dis. 2024 Dec 16;5:26330040241307962. doi: 10.1177/26330040241307962. eCollection 2024 Jan-Dec. Ther Adv Rare Dis. 2024. PMID: 39691185 Free PMC article. Review.
-
Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).J Phys Condens Matter. 2008 Feb 13;20(6):060301. doi: 10.1088/0953-8984/20/06/060301. Epub 2008 Jan 24. J Phys Condens Matter. 2008. PMID: 21693862
-
Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.Orphanet J Rare Dis. 2018 Jan 22;13(1):18. doi: 10.1186/s13023-018-0761-2. Orphanet J Rare Dis. 2018. PMID: 29357903 Free PMC article.
Cited by
-
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.Orphanet J Rare Dis. 2020 Sep 3;15(1):234. doi: 10.1186/s13023-020-01514-5. Orphanet J Rare Dis. 2020. PMID: 32883327 Free PMC article.
-
Enabling Anyone to Translate Clinically Relevant Ideas to Therapies.Pharm Res. 2017 Jan;34(1):1-6. doi: 10.1007/s11095-016-2039-5. Epub 2016 Sep 12. Pharm Res. 2017. PMID: 27620174
-
Advancing orphan drug development for rare diseases.Clin Exp Pediatr. 2024 Jul;67(7):356-357. doi: 10.3345/cep.2023.01109. Epub 2023 Nov 17. Clin Exp Pediatr. 2024. PMID: 37986564 Free PMC article. No abstract available.
-
'Advocacy groups are the connectors': Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics.Health Expect. 2022 Dec;25(6):3175-3191. doi: 10.1111/hex.13625. Epub 2022 Oct 28. Health Expect. 2022. PMID: 36307981 Free PMC article.
-
Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int. 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018. Kidney Int. 2017. PMID: 28938953 Free PMC article.
References
-
- Field MJ, Boat TF: Rare Diseases and Orphan Products: Accelerating Research and Development. Washington DC: The National Academics Press.2011. Reference Source - PubMed
-
- Grabowski P, Briest F, Baum RP, et al. : Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc). 2012;48(11):723–33. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources